Market news

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing

Video webcast now available here TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company's investment thesis, highlighti

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating payload to overcome payload-specific resistance Results strengthen the rationale for a differentiated ADC sequencing strategy as ADC use expands across oncology and more patients require treatment following relapse Akari advancing IND-enabling activities for AKTX-101 toward planned Phase 1 clinical de

AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated pancreatic cancer models Strategic research collaboration with Whitehawk Therapeutics expands potential application of Akari’s PH1 platform into dual-payload ADCs Balance sheet strengthened by approximately $8.6 million of financing during the quarter, led by long-term strategic in

Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segme

Akari Therapeutics (NASDAQ: AKTX) continues to execute on its strategy of advancing a differentiated payload platform designed for the next generation of antibody drug conjugates (ADCs). The

Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform Watch the “What This Means” video here TAMPA, Fla. and LONDON, July 22, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today that announced that its CEO, Abizer Gaslightwala, p

Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunitiesTAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics com

Akari Therapeutics is advancing a novel antibody-drug conjugate (ADC) payload designed to overcome the limitations of existing cancer therapies, with its lead candidate AKTX-101 approaching c